Patents by Inventor Shibin Zhou

Shibin Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10329858
    Abstract: The present invention relates to the field of petroleum extraction equipment, and discloses a coiled tubing unit, which comprises a vehicle body (T), a control cab (30), a coiled tubing reel (10) configured to wind coiled tubing, and a power skid (20) configured to supply power to the coiled tubing reel (10) and transported separately, wherein, the coiled tubing reel (10) and the control cab (30) are mounted on the vehicle body (T). With the coiled tubing unit provided in the present invention, the total length and total weight of the vehicle body on which the coiled tubing reel is mounted are smaller and can meet the requirements for transportation in regions where smaller vehicle dimensions and weight are specified for transportation when coiled tubing in large diameter and/or great length is transported, and the coiled tubing unit is adaptive to the operating habits, and can be deployed flexibly so that it can be used in a well field where the space is limited.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 25, 2019
    Assignee: JIANGHAN MACHINERY RESEARCH INSTITUTE LIMITED COMP
    Inventors: Huiqun He, Gao Yang, Shoujun Liu, Xuehui Li, Ge Xiong, Shibin Zhang, Jun Hao, Heping Cao, Wenyi Duan, Zhiqiang Hu, Jiafu Yan, Zhimin Yang, Fei Liu, Zhongcheng Zhou
  • Publication number: 20180161274
    Abstract: The invention provides liposome compositions comprising liposomes encapsulating cyclodextrins that both bear ionizable functional groups, such as on their solvent-exposed surfaces, and encompass therapeutic agents, as well as uses thereof.
    Type: Application
    Filed: January 14, 2015
    Publication date: June 14, 2018
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Shibin Zhou, Surojit Sur
  • Publication number: 20180086832
    Abstract: Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We generated single chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. These scFvs can be converted to full-length antibodies, termed MANAbodies, targeting “Mutation Associated Neo-Antigens” bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for peptides bound to pre-defined HLA types. In this way, we obtained scFvs, including one specific for a peptide encoded by a common KRAS mutant and another by a common EGFR mutant. Molecules targeting MANA can be developed that specifically react with mutant peptide-HLA complexes even when these peptides differ by only one amino acid from the normal, wild-type form.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 29, 2018
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Shibin Zhou, Luis Diaz, Nickolas Papadopoulos, Andrew Skora, Jackie Douglass, Michael S. Hwang
  • Publication number: 20170189526
    Abstract: Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.
    Type: Application
    Filed: July 13, 2015
    Publication date: July 6, 2017
    Applicant: The Johns Hopkins University
    Inventors: Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER, KiBem KIM
  • Publication number: 20170020931
    Abstract: The presently disclosed subject matter provides methods and kits for treating solid tumors in a subject by using a combination of anti-CTLA-4 and/or anti-PD-1 antibodies with at least one member of the group consisting of a bacterium, bacterial product, and an immunoregulatory entity. In particular embodiments, the bacteria are toxin-depleted, anaerobic bacteria, such as Clostridium novyi-NT.
    Type: Application
    Filed: March 31, 2015
    Publication date: January 26, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: SHIBIN ZHOU, BERT VOGELSTEIN, KENNETH KINZLER, KIBEM KIM, SAURABH SAHA
  • Publication number: 20160051597
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×103-1×107 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 25, 2016
    Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
  • Publication number: 20160045556
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 18, 2016
    Applicant: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
  • Publication number: 20150306184
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 29, 2015
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 8901100
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 2, 2014
    Assignee: The Johns Hopkins University
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 8691186
    Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: April 8, 2014
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
  • Publication number: 20130323167
    Abstract: Several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. Exemplary vascular-active agents include a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents.
    Type: Application
    Filed: October 20, 2011
    Publication date: December 5, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bert Vogelstein, Yuan Qiao, Xin Huang, Kenneth Kinzler, Shibin Zhou, Luis Diaz
  • Publication number: 20130315986
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Application
    Filed: August 9, 2013
    Publication date: November 28, 2013
    Applicant: Johns Hopkins University
    Inventors: Ian CHEONG, Shibin ZHOU, Kenneth W. KINZLER, Bert VOGELSTEIN
  • Patent number: 8568708
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 29, 2013
    Assignee: The John Hopkins University
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 8444963
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 21, 2013
    Assignee: John Hopkins University
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Publication number: 20130064767
    Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
    Type: Application
    Filed: August 28, 2012
    Publication date: March 14, 2013
    Applicant: The Johns Hopkins University
    Inventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
  • Patent number: 8273326
    Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: September 25, 2012
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
  • Publication number: 20110250258
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Application
    Filed: June 19, 2007
    Publication date: October 13, 2011
    Applicant: JOHNS HOPKINS UNIVERSITY
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Publication number: 20090010844
    Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 8, 2009
    Applicant: The John Hopkins University
    Inventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
  • Publication number: 20060281078
    Abstract: hFAST-1 is a human forkhead activin signal transducer gene. The hFAST-1 protein has the ability to bind to human Smad2 and activate an activin response element (ARE). The hFAST-1-dependent activation of ARE is dependent on endogenous Smad4 and stimulation of the TGF-? receptor. The hFAST-1 protein binds to a novel DNA motif, TGT(G/T)(T/G)ATT, which is present within the ARE. This motif is important for the activation of genes responsive to ligands of the TGF-? family. The invention includes tools for investigating the TGF-? signaling pathway and screening for compounds which modulate the action of TGF-?.
    Type: Application
    Filed: February 6, 2001
    Publication date: December 14, 2006
    Inventors: Shibin Zhou, Leigh Zawel, Bert Vogelstein, Kenneth Kinzler
  • Patent number: 6225441
    Abstract: hFAST-1 is a human forkhead activin signal transducer gene. The hFAST-1 protein has the ability to bind to human Smad2 and activate an activin response element (ARE). The hFAST-1-dependent activation of ARE is dependent on endogenous Smad4 and stimulation of the TGF-&bgr; receptor. The hFAST-1 protein binds to a novel DNA motif, TGT(G/T)(T/G)ATT, which is present within the ARE. This motif is important for the activation of genes responsive to ligands of the TGF-&bgr; family. The invention includes tools for investigating the TGF-&bgr; signaling pathway and screening for compounds which modulate the action of TGF-&bgr;.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: May 1, 2001
    Assignee: The Johns Hopkins University
    Inventors: Shibin Zhou, Leigh Zawel, Bert Vogelstein, Kenneth W. Kinzler